---
title: "Metabolomics identifies lipid and amino acid signatures linked to disease severity in multiple scl"
id: "biorxiv-3-metabolomics-reveals-lipid-and-amino-acid-signatures-of-disease-severity-in"
canonical_url: "https://medichelpline.com/clinical-feed/biorxiv-3-metabolomics-reveals-lipid-and-amino-acid-signatures-of-disease-severity-in"
content_type: "clinical_feed_article"
specialty: "Neurology"
source_name: "bioRxiv (Biomedical Preprints)"
source_url: "https://www.biorxiv.org/content/10.64898/2026.08.04.742797v1?rss=1"
published_at: "2026-08-10T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Metabolomics identifies lipid and amino acid signatures linked to disease severity in multiple scl
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/biorxiv-3-metabolomics-reveals-lipid-and-amino-acid-signatures-of-disease-severity-in
- **Specialty:** [Neurology](https://medichelpline.com/clinical-feed/neurology.md)
- **Primary Source:** bioRxiv (Biomedical Preprints)
- **Source URL:** [Original Journal Publication](https://www.biorxiv.org/content/10.64898/2026.08.04.742797v1?rss=1)
- **Published At:** 2026-08-10T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Plasma **metabolomics** profiling was performed in a large cohort to investigate metabolic signatures associated with **multiple sclerosis (MS)** diagnosis and disease activity. - The study included 411 deeply phenotyped patients with MS and 46,443 controls; 162 metabolites were measured and grouped into 30 biologically related metabolite groups. - Fourteen of 30 metabolite groups showed significant association with MS after false discovery rate correction, with positive associations for **atherogenic lipoproteins**, glycine, cholines, and saturated fatty acids. - Negative associations with MS were observed for aromatic amino acids, branched-chain amino acids, alanine, and citrate. - Differential network enrichment analysis revealed two dysregulated subnetworks: one involving amino acid and energy metabolism and another involving lipid and lipoprotein metabolism. - Five metabolite groups were negatively associated with disability: small high-density lipoprotein particles, histidine, branched-chain amino acids, albumin, and aromatic amino acids. - The **omega-6/omega-3 ratio** was significantly associated with recent relapse (OR = 1.92, FDR-p = 0.030) and showed a nominal association with future MRI activity, particularly in patients on moderate or high-efficacy disease-modifying therapy. - The metabolic signature identified in established MS was not detectable in 25 pre-diagnosis samples collected prior to the first demyelinating event. - Findings point to coordinated dysregulation of **amino acid** and **lipoprotein metabolism** as hallmarks of established MS and identify the omega-6/omega-3 ratio as a novel marker linked to inflammatory disease activity. - The article is a preprint and has not undergone peer review; competing interests and funder information are reported by the authors.
## Clinical Analysis & Structured Key Points
[](https://www.biorxiv.org/cdn-cgi/content?id=UBdfUHNONckt8PXG9Wl3XgeTQCclN1g8LbAnReMLBdI-1786408616.591038-1.2.1.1-p9yA5zhjloK39bgg30mx7T8HN2q5F2bhXeThfC95_bw2D0LuNXPNF1Jea8WJbMnV) [Skip to main content](https://www.biorxiv.org/content/10.64898/2026.08.04.742797v1?rss=1#main-content) [![bioRxiv](https://www.biorxiv.org/sites/default/files/biorxiv_article_logo.jpg)](https://www.biorxiv.org/) * [Home](https://www.biorxiv.org/) * [Submit](https://www.biorxiv.org/submit-a-manuscript) * [FAQ](https://www.biorxiv.org/about/FAQ) * [Blog](https://connect.biorxiv.org/news/) * [ALERTS / RSS](https://www.biorxiv.org/content/alertsrss) * [Resources](https://connect.biorxiv.org/resources/) * [About](https://www.biorxiv.org/content/about-biorxiv) * [Channels](https://www.biorxiv.org/content/10.64898/2026.08.04.742797v1?rss=1) * [4D Nucleome](https://connect.biorxiv.org/relate/content/66) * [Academia Sinica](https://connect.biorxiv.org/group/content/38) * [Advances in Genome Biology and Technology (AGBT) General Meeting 2016 #AGBT16](https://connect.biorxiv.org/relate/content/10) * [Albert Einstein College of Medicine](https://connect.biorxiv.org/group/content/4) * [Aligning Science Across Parkinson's (ASAP)](https://connect.biorxiv.org/relate/content/195) * [Allen Institute for Cell Science](https://connect.biorxiv.org/relate/content/71) * [Arc Institute](https://connect.biorxiv.org/relate/content/224) * [Babraham Institute](https://connect.biorxiv.org/relate/content/197) * [BICCN/BICAN](https://connect.biorxiv.org/relate/content/208) * [BioImaging North America](https://connect.biorxiv.org/relate/content/194) * [Biology of Genomes 2016 #BOG16](https://connect.biorxiv.org/relate/content/19) * [Breakthrough Discoveries for Thriving with Bipolar Disorder](https://connect.biorxiv.org/relate/content/236) * [Brown University](https://connect.biorxiv.org/group/content/9) * [California Institute of Technology](https://connect.biorxiv.org/group/content/32) * [Carnegie Mellon University](https://connect.biorxiv.org/group/content/19) * [Case Western Reserve University](https://connect.biorxiv.org/group/content/36) * [Central Oxford Structural Microscopy and Imaging](https://connect.biorxiv.org/relate/content/143) * [Centre for Microbiology and Environmental Systems Science](https://connect.biorxiv.org/relate/content/190) * [Chan Zuckerberg Biohub](https://connect.biorxiv.org/relate/content/121) * [Columbia University](https://connect.biorxiv.org/group/content/27) * [Donders Institute for Brain, Cognition and Behaviour](https://connect.biorxiv.org/relate/content/184) * [DREAM](https://connect.biorxiv.org/relate/content/153) * [Drug Development and Clinical Therapeutics](https://connect.biorxiv.org/relate/content/52) * [ENCODE](https://connect.biorxiv.org/relate/content/177) * [Ernst Strüngmann Institute (ESI) for Neuroscience](https://connect.biorxiv.org/relate/content/211) * [European Molecular Biology Laboratory (EMBL)](https://connect.biorxiv.org/relate/content/159) * [Francis Crick Institute](https://connect.biorxiv.org/relate/content/88) * [Fred Hutchinson Cancer Center](https://connect.biorxiv.org/group/content/28) * [Georgia Institute of Technology](https://connect.biorxiv.org/group/content/20) * [Harvard Program in Therapeutic Sciences](https://connect.biorxiv.org/relate/content/151) * [The Howard Hughes Medical Institute (HHMI)](https://connect.biorxiv.org/relate/content/227) * [Human Cell Atlas](https://connect.biorxiv.org/relate/content/163) * [Human Pangenome Reference Consortium (HPRC)](https://connect.biorxiv.org/relate/content/215) * [IMO Workshop](https://connect.biorxiv.org/relate/content/8) * [Impact of Genomic Variation on Function (IGVF)](https://connect.biorxiv.org/relate/content/214) * [Institut Pasteur](https://connect.biorxiv.org/relate/content/235/channel) * [Institute of Science and Technology Austria](https://connect.biorxiv.org/group/content/12) * [International Human Epigenome Consortium (IHEC)](https://connect.biorxiv.org/relate/content/219) * [International Mouse Phenotyping Consortium (IMPC)](https://connect.biorxiv.org/relate/content/185) * [Iowa State University](https://connect.biorxiv.org/group/content/6) * [Johns Hopkins University](https://connect.biorxiv.org/group/content/47) * [Mathematical Oncology](https://connect.biorxiv.org/relate/content/1) * [Micron Oxford](https://connect.biorxiv.org/relate/content/116) * [Michigan State University](https://connect.biorxiv.org/group/content/7) * [Morgridge Institute](https://connect.biorxiv.org/group/content/57) * [National Taiwan University](https://connect.biorxiv.org/group/content/39) * [NCI Cancer Systems Biology Consortium](https://connect.biorxiv.org/relate/content/210) * [NF Open Science Initiative](https://connect.biorxiv.org/relate/content/213) * [NCI Human Tumor Atlas Network](https://connect.biorxiv.org/relate/content/171) * [Neuromatch Conference](https://connect.biorxiv.org/relate/content/209) * [NeurotechEU](https://connect.biorxiv.org/relate/content/189) * [North Carolina State University](https://connect.biorxiv.org/group/content/37) * [Northeastern University](https://connect.biorxiv.org/group/content/54) * [Oregon Health & Sciences University](https://connect.biorxiv.org/group/content/22) * [RNA Therapeutics Institute at UMass Chan Med School](https://connect.biorxiv.org/relate/content/243) * [Rosetta Commons](https://connect.biorxiv.org/relate/content/191) * [Rutgers University](https://connect.biorxiv.org/group/content/31) * [SeroNet](https://connect.biorxiv.org/relate/content/192) * [Simons Foundation Autism Research Initiative (SFARI)](https://connect.biorxiv.org/relate/content/74) * [Society for Molecular Biology and Evolution #SMBE2016](https://connect.biorxiv.org/relate/content/29) * [Somatic Cell Genome Editing Program](https://connect.biorxiv.org/relate/content/167) * [Somatic Mosaicism across the Human Tissues Network](https://connect.biorxiv.org/relate/content/222) * [SPARC](https://connect.biorxiv.org/relate/content/187) * [Stowers Institute for Medical Research](https://connect.biorxiv.org/group/content/3) * [Stockholm University](https://connect.biorxiv.org/group/content/14) * [Tel Aviv University](https://connect.biorxiv.org/group/content/8) * [The Michael J. Fox Foundation](https://connect.biorxiv.org/relate/content/207) * [The Rockefeller University](https://connect.biorxiv.org/group/content/2) * [The Sainsbury Laboratory](https://connect.biorxiv.org/relate/content/98) * [The Whitehead Institute](https://connect.biorxiv.org/relate/content/212) * [University of Connecticut Health Center](https://connect.biorxiv.org/group/content/16) * [University of California, Berkeley](https://connect.biorxiv.org/group/content/13) * [University of California, San Diego](https://connect.biorxiv.org/group/content/41) * [University of California, San Francisco](https://connect.biorxiv.org/group/content/10) * [University of Chicago](https://connect.biorxiv.org/group/content/42) * [University of Geneva](https://connect.biorxiv.org/group/content/26) * [University of Guelph](https://connect.biorxiv.org/group/content/23) * [University of Hong Kong](https://connect.biorxiv.org/group/content/29) * [University of Illinois Chicago](https://connect.biorxiv.org/group/content/43) * [University of Iowa](https://connect.biorxiv.org/group/content/24) * [University of Kansas](https://connect.biorxiv.org/group/content/33) * [University of Massachusetts Chan Medical School](https://connect.biorxiv.org/group/content/44) * [University of New South Wales](https://connect.biorxiv.org/group/content/25) * [University of Ottawa](https://connect.biorxiv.org/group/content/35) * [University of Sydney](https://connect.biorxiv.org/group/content/50) * [Vanderbilt University](https://connect.biorxiv.org/group/content/30) * [Vienna BioCenter](https://connect.biorxiv.org/relate/content/186) * [Washington University in St. Louis](https://connect.biorxiv.org/group/content/11) * [Weizmann Institute of Science](https://connect.biorxiv.org/group/content/15) * [Yale University](https://connect.biorxiv.org/group/content/53) Search for this keyword [Advanced Search](https://www.biorxiv.org/search) New Results Follow this preprint # Metabolomics reveals lipid and amino acid signatures of disease severity in multiple sclerosis [ View ORCID Profile](http://orcid.org/0000-0001-9826-7827)Rachel Rodin, [ View ORCID Profile](http://orcid.org/0000-0001-5272-2425)Brian C Healy, [ View ORCID Profile](http://orcid.org/0000-0002-1244-1802)Mariann Polgar-Turcsanyi, [ View ORCID Profile](http://orcid.org/0000-0002-8257-1901)Hrishikesh A Lokhande, [ View ORCID Profile](http://orcid.org/0000-0002-9897-4422)Tanuja Chitnis doi: https://doi.org/10.64898/2026.08.04.742797 This article is a preprint and has not been certified by peer review [[what does this mean?](https://www.biorxiv.org/about/FAQ#unrefereed)]. Rachel Rodin Mass General Brigham * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Rachel%2BRodin%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Rodin%20R&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3ARachel%2BRodin%2B) * [ORCID record for Rachel Rodin](http://orcid.org/0000-0001-9826-7827 "Open in new tab") Brian C Healy Mass General Brigham * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Brian%2BC%2BHealy%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Healy%20BC&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3ABrian%2BC%2BHealy%2B) * [ORCID record for Brian C Healy](http://orcid.org/0000-0001-5272-2425 "Open in new tab") Mariann Polgar-Turcsanyi Mass General Brigham * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Mariann%2BPolgar-Turcsanyi%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Polgar-Turcsanyi%20M&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AMariann%2BPolgar-Turcsanyi%2B) * [ORCID record for Mariann Polgar-Turcsanyi](http://orcid.org/0000-0002-1244-1802 "Open in new tab") Hrishikesh A Lokhande Mass General Brigham * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Hrishikesh%2BA%2BLokhande%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Lokhande%20HA&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3AHrishikesh%2BA%2BLokhande%2B) * [ORCID record for Hrishikesh A Lokhande](http://orcid.org/0000-0002-8257-1901 "Open in new tab") Tanuja Chitnis Mass General Brigham * [Find this author on Google Scholar](https://www.biorxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Tanuja%2BChitnis%2B "Open in new tab") * [Find this author on PubMed](https://www.biorxiv.org/lookup/external-ref?access_num=Chitnis%20T&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.biorxiv.org/search/author1%3ATanuja%2BChitnis%2B) * [ORCID record for Tanuja Chitnis](http://orcid.org/0000-0002-9897-4422 "Open in new tab") * For correspondence: tchitnis@bwh.harvard.edu * [Abstract](https://www.biorxiv.org/content/10.64898/2026.08.04.742797v1)[](https://www.biorxiv.org/panels_ajax_tab/biorxiv_tab_art/node:5694344/1) * [Info/History](https://www.biorxiv.org/content/10.64898/2026.08.04.742797v1.article-info)[](https://www.biorxiv.org/panels_ajax_tab/biorxiv_tab_info/node:5694344/1) * [Metrics](https://www.biorxiv.org/content/10.64898/2026.08.04.742797v1.article-metrics)[](https://www.biorxiv.org/panels_ajax_tab/article_tab_metrics/node:5694344/1) * [Supplementary material](https://www.biorxiv.org/content/10.64898/2026.08.04.742797v1.supplementary-material)[](https://www.biorxiv.org/panels_ajax_tab/biorxiv_tab_data/node:5694344/1) * [ Preview PDF](https://www.biorxiv.org/content/10.64898/2026.08.04.742797v1.full.pdf+html)[](https://www.biorxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:5694344/1) ![Loading](https://www.biorxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Objective: Plasma metabolomics offers insight into multiple sclerosis (MS) pathophysiology, but existing studies are limited by small sample sizes and incomplete clinical data. Methods: We conducted plasma metabolomic profiling of 411 deeply phenotyped patients with MS and 46,443 controls, analyzing 162 metabolites in 30 biologically related metabolite groups. We characterized associations with MS diagnosis, disability, disease subtype, and inflammatory disease activity using regression and differential network enrichment analysis. We additionally examined 25 pre-diagnosis individuals whose samples were collected before their first demyelinating event. Results: Fourteen of 30 metabolite groups were associated with MS after false discovery rate correction, with the strongest positive associations observed for atherogenic lipoproteins, glycine, cholines, and saturated fatty acids, and the strongest negative associations for aromatic amino acids, branched-chain amino acids, alanine, and citrate. Differential network enrichment analysis identified two dysregulated subnetworks encompassing amino acid and energy metabolism and lipid and lipoprotein metabolism. Five metabolite groups were negatively associated with disability: small high-density lipoprotein particles, histidine, branched-chain amino acids, albumin, and aromatic amino acids. The omega-6/omega-3 fatty acid ratio was significantly associated with recent relapse (OR = 1.92, FDR-p = 0.030) and nominally associated with future MRI activity, especially in patients on moderate or high-efficacy disease-modifying therapy. The MS metabolic signature was not detectable in pre-diagnosis samples. Interpretation: These findings highlight coordinated dysregulation of amino acid and lipoprotein metabolism as hallmarks of established MS and identify a novel association of the omega-6/omega-3 ratio with inflammatory disease activity. ### Competing Interest Statement BC Healy has received research support to his institution from Novartis and Genzyme. T. Chitnis has received compensation for consulting from Bristol Myers Squibb, Cabaletta Bio, Cycle Pharmaceuticals*, Genentech, Janssen, Merck KGaA, MJH Life Sciences, Novartis Pharmaceuticals AG, Novartis Pharmaceuticals KK, Octave Bioscience, F. Hoffmann-La Roche Ltd, Sanofi, Siemens*, and UCB Biopharma*. T. Chitnis has received compensation for speaking engagements from Intellisphere, LLC* and Prime Education, LLC*. T. Chitnis has received research support from the BrightFocus Foundation, Bristol Myers Squibb, Genentech, EMD Serono, I-Mab Biopharma, Massachusetts Life Sciences Center, NIH, National MS Society, Novartis Pharmaceuticals, Octave Bioscience, Sanofi Genzyme, Tiziana Therapeutics, US Department of Defense, and Wesley Clover International. All activities and funding have occurred within the past 24 months (*relationship has since ended) and disclosures do not conflict with the work being presented. The remaining authors have no competing interests to disclose. ## Funder Information Declared National Multiple Sclerosis Society, FAN-2407-43752 Copyright The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](http://creativecommons.org/licenses/by/4.0/). bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.biorxiv.org/content/10.64898/2026.08.04.742797v1?rss=1#page) [ Previous](https://www.biorxiv.org/content/10.64898/2026.08.04.737285v1 "MicroRNA correlates of resilience to Alzheimer's disease identify candidate therapeutic targets for neuroprotection")[Next ](https://www.biorxiv.org/content/10.64898/2026.08.04.742795v1 "Cholesterol-Mediated Modulation of Collecting Lymphatic Vessel Contractility: Exploring Cholesterol Depletion as a Therapeutic Alternative to Improve Lymphatic Function in Hypercholesterolemia") Posted August 10, 2026. [ Download PDF](https://www.biorxiv.org/content/10.64898/2026.08.04.742797v1.full.pdf) Print/Save Options [Download PDF](https://www.biorxiv.org/content/biorxiv/early/2026/08/10/2026.08.04.742797.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.biorxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [Supplementary Material ](https://www.biorxiv.org/content/10.64898/2026.08.04.742797v1.supplementary-material) [ Email](https://www.biorxiv.org/ "Email this Article") [ Share](https://www.biorxiv.org/) Metabolomics reveals lipid and amino acid signatures of disease severity in multiple sclerosis Rachel Rodin, Brian C Healy, Mariann Polgar-Turcsanyi, Hrishikesh A Lokhande, Tanuja Chitnis bioRxiv 2026.08.04.742797; doi: https://doi.org/10.64898/2026.08.04.742797 This article is a preprint and has not been certified by peer review [[what does this mean?](https://www.biorxiv.org/about/FAQ#unrefereed)]. Share This Article: Copy [![Twitter logo](https://www.biorxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.biorxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.biorxiv.org%2Fcontent%2F10.64898%2F2026.08.04.742797v1%26text%3DMetabolomics%2520reveals%2520lipid%2520and%2520amino%2520acid%2520signatures%2520of%2520disease%2520severity%2520in%2520multiple%2520sclerosis "Share this on Twitter") [![Facebook logo](https://www.biorxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.biorxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.biorxiv.org%2Fcontent%2F10.64898%2F2026.08.04.742797v1%26t%3DMetabolomics%2520reveals%2520lipid%2520and%2520amino%2520acid%2520signatures%2520of%2520disease%2520severity%2520in%2520multiple%2520sclerosis "Share on Facebook") [![LinkedIn logo](https://www.biorxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.biorxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.biorxiv.org%2Fcontent%2F10.64898%2F2026.08.04.742797v1%26title%3DMetabolomics%2520reveals%2520lipid%2520and%2520amino%2520acid%2520signatures%2520of%2520disease%2520severity%2520in%2520multiple%2520sclerosis%26summary%3D%26source%3DbioRxiv "Publish thi
## Related Clinical Research

- [2026 Stroke Rehabilitation Guideline: Start Early and Address Physical, Cognitive, and Mental Heal](https://medichelpline.com/clinical-feed/medical-news-today-0-stroke-rehab-guidelines-emphasize-early-support-for-physical-cognitive-and.md)
- [Hormone replacement therapy timing and menopause type linked to dementia risk in large UK study](https://medichelpline.com/clinical-feed/medical-news-today-1-menopause-type-and-hrt-timing-influence-dementia-risk-large-study-suggests.md)
- [Integrated multi-omics detection of m6A‑SNP–related diagnostic biomarkers for ALS](https://medichelpline.com/clinical-feed/frontiers-in-immunology-11-integrated-multi-omics-identification-of-m6a-snp-related-diagnostic-biomarkers.md)
- [Climate change worsens health for people with chronic illness](https://medichelpline.com/clinical-feed/stat-news-1-opinion-climate-change-is-making-people-with-chronic-illness-even-sicker.md)
- [Resveratrol and the neuroinflammation axis in Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, and cerebral ischemia](https://medichelpline.com/clinical-feed/frontiers-in-immunology-8-resveratrol-and-the-neuroinflammation-axis-in-alzheimer-s-disease-parkinson-s-disease-multiple-sclerosis-and-cerebral-ischemia.md)

## Navigation
- [← Back to Neurology Feed](https://medichelpline.com/clinical-feed/neurology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.